IGF2BP3 Antibody (DE-7): sc-100766
- IGF2BP3 Antibody (DE-7) is a mouse monoclonal IgM provided at 200 µl ascites
- raised against recombinant IGF2BP3 of human origin
- recommended for detection of IGF2BP3 of mouse, rat and human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IGF2BP3 Antibody (DE-7). This work is in progress.
QUICK LINKS
SEE ALSO...
IGF2BP3 Antibody (DE-7) is a mouse monoclonal IgM antibody that detects IGF2BP3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). IGF2BP3 (DE-7) antibody is available in a non-conjugated form, allowing for versatile experimental use. The insulin-like growth factor 2 mRNA binding proteins (IGF2BPs) play a crucial role in regulating RNA metabolism and synthesis, which is vital for cellular function and development. Specifically, IGF2BP3 interacts with various mRNAs, including those encoding c-Myc and IGF-II, thereby influencing cell proliferation and growth. IGF2BP3 is particularly significant in cancer biology, as IGF2BP3 is associated with the progression of several malignancies, including colon cancer, sarcomas, and breast cancer. IGF2BP3 has been linked to high-grade dysplastic lesions in pancreatic ductal epithelium, making IGF2BP3 a potential biomarker for carcinomas. Additionally, IGF2BP3′s ability to modulate the stability and translation of target mRNAs underscores IGF2BP3′s importance in tumorigenesis and cellular response to growth factors.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IGF2BP3 Antibody (DE-7) References:
- RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. | Wang, X., et al. 2021. J Exp Clin Cancer Res. 40: 80. PMID: 33637103
- METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. | Wan, W., et al. 2022. Mol Cancer. 21: 60. PMID: 35197058
- IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. | Xu, X., et al. 2022. Mater Today Bio. 17: 100503. PMID: 36457846
- Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. | Lin, Z., et al. 2023. Cancer Res. 83: 2187-2207. PMID: 37061993
- m6 A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. | Yang, X., et al. 2023. Adv Sci (Weinh). 10: e2206744. PMID: 37171793
- IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification. | Li, S., et al. 2023. Cell Death Discov. 9: 164. PMID: 37188676
- A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability. | Li, K., et al. 2023. Nat Commun. 14: 6876. PMID: 37898647
- m6A modification negatively regulates translation by switching mRNA from polysome to P-body via IGF2BP3. | Shan, T., et al. 2023. Mol Cell. 83: 4494-4508.e6. PMID: 38016476
- IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD. | Han, C., et al. 2024. Cell Death Dis. 15: 138. PMID: 38355626
- IGF2BP3 promotes mRNA degradation through internal m7G modification. | Liu, C., et al. 2024. Nat Commun. 15: 7421. PMID: 39198433
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF2BP3 Antibody (DE-7) | sc-100766 | 200 µl ascites | $339.00 |